SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group Inc. a late-stage clinical biopharmaceutical company focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS) a cancer immunotherapeutic agent that targets Wilms tumor 1 which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co. Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai) Inc. for the development and commercialization of GFH009 a highly selective small molecule CDK9 inhibitor currently under Phase 1 clinical trials. The company is headquartered in New York New York.